Monoclonal Antibody
Affect of Daratumumab on Laboratory Blood Test Results
August 22, 2017Do monoclonal antibodies other than daratumumab cause false positives in the blood antibody screen and crossmatch obtained prior to a transfusion?
Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
August 18, 2017Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
Value of Type and Crossmatch Prior to Daratumumab Administration
August 14, 2017If type and crossmatch is obtained before initiating treatment with daratumumab, what good would that do if a transfusion is required a month later?
Type and Crossmatch Needed Before Initiating Treatment With Daratumumab
July 11, 2017Why is a type and crossmatch needed before starting patients on treatment with daratumumab (Darzalex)?
Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
June 20, 2017Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.
Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients
June 12, 2017The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.
Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC
June 09, 2017Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery
June 09, 2017Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.
Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival
June 05, 2017Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
April 20, 2017A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma
November 01, 2016Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.
Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia
June 23, 2016Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors
June 10, 2016The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
June 07, 2016Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma
June 07, 2016At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma
June 06, 2016Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
Daratumumab Demonstrates Encouraging Efficacy in Patients With Pretreated or Refractory Multiple Myeloma
January 22, 2016Heavily pretreated and refractory patients with multiple myeloma had encouraging efficacy results with daratumumab monotherapy.
Experimental treatment shows early promise for advanced neuroblastoma in children
May 23, 2014Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.
ONA Articles
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |